NASDAQ:BCRX BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis $7.98 -0.15 (-1.85%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.91▼$8.2550-Day Range$6.41▼$8.6952-Week Range$4.03▼$8.88Volume1.29 million shsAverage Volume3.23 million shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice Target$14.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get BioCryst Pharmaceuticals alerts: Email Address BioCryst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside77.5% Upside$14.17 Price TargetShort InterestBearish12.02% of Shares Sold ShortDividend StrengthN/ASustainability-1.85Upright™ Environmental ScoreNews Sentiment0.00Based on 4 Articles This WeekInsider TradingSelling Shares$82,486 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.45) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector296th out of 910 stocksBiological Products, Except Diagnostic Industry41st out of 155 stocks 3.4 Analyst's Opinion Consensus RatingBioCryst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioCryst Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about BioCryst Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.02% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverBioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in BioCryst Pharmaceuticals has recently increased by 1.76%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioCryst Pharmaceuticals does not currently pay a dividend.Dividend GrowthBioCryst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.Environmental SustainabilityThe Environmental Impact score for BioCryst Pharmaceuticals is -1.85. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 4 news articles for BioCryst Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCryst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,486.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of BioCryst Pharmaceuticals is held by insiders.Percentage Held by Institutions85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioCryst Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.45) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCryst Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCryst Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCryst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Read More BCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCRX Stock News HeadlinesSeptember 6 at 2:00 AM | globenewswire.comBioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin SymposiumSeptember 5 at 1:00 PM | finance.yahoo.comBioCryst Appoints Dr. Donald Fong Chief Medical OfficerSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…September 5 at 1:00 PM | markets.businessinsider.comBioCryst Pharma Appoints Donald Fong As New Chief Medical OfficerSeptember 4 at 7:00 AM | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 29, 2024 | americanbankingnews.comBrokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $14.17August 22, 2024 | globenewswire.comBioCryst to Present at Upcoming Investor ConferencesAugust 6, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Timothy Sykes (Ad)Tim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…August 6, 2024 | msn.comBioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | markets.businessinsider.comBioCryst Pharmaceuticals: Strong Orladeyo Sales and Promising Pipeline Justify Buy RatingAugust 6, 2024 | bizjournals.comDurham firm hikes revenue target by $30 millionAugust 6, 2024 | msn.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2024 Earnings Call TranscriptAugust 5, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 5, 2024 | seekingalpha.comBioCryst Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 5, 2024 | msn.comBioCryst Pharmaceuticals Non-GAAP EPS of -$0.06 beats by $0.10, revenue of $109.33M beats by $11.01MAugust 5, 2024 | globenewswire.comBioCryst Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 2, 2024 | globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive BCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:BCRX CUSIP09058V10 CIK882796 Webwww.biocryst.com Phone(919) 859-1302Fax919-859-1314Employees530Year Founded1986Price Target and Rating Average Stock Price Target$14.17 High Stock Price Target$30.00 Low Stock Price Target$7.00 Potential Upside/Downside+77.5%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-226,540,000.00 Net Margins-38.18% Pretax Margin-38.33% Return on EquityN/A Return on Assets-28.14% Debt Debt-to-Equity RatioN/A Current Ratio2.82 Quick Ratio2.78 Sales & Book Value Annual Sales$382.24 million Price / Sales4.31 Cash FlowN/A Price / Cash FlowN/A Book Value($2.30) per share Price / Book-3.47Miscellaneous Outstanding Shares206,377,000Free Float196,471,000Market Cap$1.65 billion OptionableOptionable Beta1.88 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Jon P. Stonehouse (Age 63)CEO, President & Executive Director Comp: $1.23MMr. Anthony J. Doyle (Age 44)Senior VP, CFO & Treasurer Comp: $845.93kMs. Alane P. Barnes (Age 58)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $794.75kMs. Jinky Ang RosselliChief Data & Insights OfficerMr. Philip GeorgeChief Strategy OfficerMr. Clayton FletcherChief Business Development OfficerMore ExecutivesKey CompetitorsAligos TherapeuticsNASDAQ:ALGSTaysha Gene TherapiesNASDAQ:TSHANantKwestNASDAQ:NKAdaptimmune TherapeuticsNASDAQ:ADAPVaxartNASDAQ:VXRTView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 26,571 shares on 9/5/2024Ownership: 0.013%Algert Global LLCBought 55,311 shares on 8/16/2024Ownership: 0.171%Northeast Financial Consultants IncBought 5,000 shares on 8/16/2024Ownership: 0.032%Creative PlanningBought 20,014 shares on 8/16/2024Ownership: 0.023%Mackenzie Financial CorpSold 4,344 shares on 8/15/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions BCRX Stock Analysis - Frequently Asked Questions How have BCRX shares performed this year? BioCryst Pharmaceuticals' stock was trading at $5.99 on January 1st, 2024. Since then, BCRX shares have increased by 33.2% and is now trading at $7.98. View the best growth stocks for 2024 here. How were BioCryst Pharmaceuticals' earnings last quarter? BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Monday, August, 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The company's revenue for the quarter was up 34.9% on a year-over-year basis. What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO? 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend. Who are BioCryst Pharmaceuticals' major shareholders? Top institutional shareholders of BioCryst Pharmaceuticals include Avoro Capital Advisors LLC (6.09%), Deerfield Management Company L.P. Series C (3.94%), Rice Hall James & Associates LLC (1.01%) and Millennium Management LLC (0.85%). Insiders that own company stock include Jon P Stonehouse, Yarlagadda S Babu, Helen M Thackray, Anthony Doyle, Nancy J Hutson, Steven K Galson, Alan G Levin, Amy E Mckee, Machelle Sanders, Michael L Jones, Vincent Milano and George B Abercrombie. View institutional ownership trends. How do I buy shares of BioCryst Pharmaceuticals? Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioCryst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX) and La Jolla Pharmaceutical (LJPC). This page (NASDAQ:BCRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.